Company intelligence / Profile preview

Brava Pharmaceuticals

Oxford, Oxfordshire, United Kingdom

Ownership: Private
Development stage: Other

Overview

Brava Pharmaceuticals is a biotechnology company focused on the discovery and development of precision medicines for rare neurodevelopmental and neurological disorders. The company primarily targets genetic epilepsies, with a lead program, BRAV-001, aimed at treating Dravet Syndrome by modulating the SCN1A sodium channel. Brava utilizes a specialized platform to identify small molecules that can restore physiological function in genetically defined patient populations. Headquartered in the United Kingdom, the company is led by industry veterans with extensive experience in CNS drug development and ion channel pharmacology.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Brava Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brava Pharmaceuticals.

Explore the full profile